COGT
HEALTHCARECogent Biosciences Inc
AI Insight
What's Moving COGT Today?
No stock-specific AI insight has been generated for COGT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$7.03$43.73
$37.53
Fundamentals
Market Cap$6.1B
P/E Ratio—
EPS$-2.17
Dividend Yield—
Dividend / Share—
ROE-85.7%
Profit Margin—
Debt / Equity—
Trading
Volume4.9M
Avg Volume (10D)—
Shares Outstanding170.9M
COGT News
24 articles- Is Cogent Biosciences (COGT) ’s New Cancer Drug 100 Times More Precise Than What’s Already on the Market?Yahoo Finance·Jun 22, 2026
- Cogent Biosciences Inc (COGT) Dividends & Stock Splits: Historical Payouts and Event TimelineTradingKey·Jun 18, 2026
- Cogent Biosciences (COGT) Stock Can APEX Trial Progress Justify A 10.6x P B RatioSimply Wall Street·Jun 18, 2026
- Cogent Biosciences' Potential Rare Blood Disease Treatment Meets Endpoints in Clinical TrialYahoo Finance·Jun 12, 2026
- Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) CongressYahoo Finance·Jun 12, 2026
- Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) CongressYahoo Finance·Jun 12, 2026
- How Investors May Respond To Cogent Biosciences (COGT) Priority Review For Bezuclastinib GIST RegimenYahoo Finance·Jun 10, 2026
- Is Cogent Biosciences, Inc. (COGT) A Good Stock To Buy Now?Yahoo Finance·Jun 7, 2026
- This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First QuarterMotley Fool·May 31, 2026
- Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual MeetingYahoo Finance·May 30, 2026
- Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GISTYahoo Finance·May 28, 2026
- Assessing Cogent Biosciences (COGT) Valuation After A Strong Year And Recent Share Price PullbackYahoo Finance·May 26, 2026
- What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock SurgeMotley Fool·May 23, 2026
- Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock RallyMotley Fool·May 23, 2026
- What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA FilingMotley Fool·May 18, 2026
- Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems BullishMotley Fool·May 18, 2026
- Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in SharesMotley Fool·May 17, 2026
- Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More SharesMotley Fool·May 17, 2026
- This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 MillionMotley Fool·May 17, 2026
- This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 MillionMotley Fool·May 17, 2026
- Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying.Yahoo Finance·May 15, 2026
- Cogent Biosciences (NASDAQ: COGT) group reports 9,043,903 sharesStock Titan·May 15, 2026
- Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 CongressYahoo Finance·May 12, 2026
- Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026GlobeNewswire Inc.·Apr 17, 2026
All 24 articles loaded
Price Data
Open$36.47
Previous Close$36.31
Day High$38.60
Day Low$36.47
52 Week High$43.73
52 Week Low$7.03
52-Week Range
$7.03$43.73
$37.53
Fundamentals
Market Cap$6.1B
P/E Ratio—
EPS$-2.17
Dividend Yield—
Dividend / Share—
ROE-85.7%
Profit Margin—
Debt / Equity—
Trading
Volume4.9M
Avg Volume (10D)—
Shares Outstanding170.9M
About Cogent Biosciences Inc
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. The company is headquartered in Cambridge, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—